SFX by Ex Libris Inc.

Title:	Synthetic antibodies: Concepts, potential and practical considerations
Source:	Methods [1046-2023] Miersch, S yr:2012

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Geyer, John R. "Recombinant antibodies and in vitro selection technologies." Methods in molecular biology 901 (2012): 11-32.
description	2.	Koo, H. "In Vivo Targeted Delivery of Nanoparticles for Theranosis." Accounts of chemical research 44.10 (2011): 1018-1028.
description	3.	Oliveira, Maria Leonor S L. "Expression of Streptococcus pneumoniae antigens, PsaA (pneumococcal surface antigen A) and PspA (pneumococcal surface protein A) by Lactobacillus casei." FEMS microbiology letters 227.1 (2003): 25-31.
description	4.	Rizk, S. "Allosteric control of ligand-binding affinity using engineered conformation-specific effector proteins." Nature structural & molecular biology 18.4 (2011): 437-42.
description	5.	Sidhu, Sachdev S. "Synthetic therapeutic antibodies." Nature chemical biology 2.12 (2006): 682-688.
description	6.	Pollack, A. "Genentech Caps Cost of cancer Drug for Some Patients." New York Times 156.53730 (2006).
description	7.	Tinberg, Christine E. "Computational design of ligand-binding proteins with high affinity and selectivity." Nature 501.7466 (2013): 212-216.
description	8.	Tonikian, R. "Selecting and purifying autonomous human variable heavy (VH) domains." Methods in molecular biology 911 (2012): 327-353.
description	9.	Niederfellner, G. "Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies." Blood 118.2 (2011): 358-367.
description	10.	Maassen, M. "Instruments for oral disease-intervention strategies : recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis." Vaccine 17.17 (1999): 2117-28.
description	11.	Liu, L. "Loop 5-directed Compounds Inhibit Chimeric Kinesin-5 Motors IMPLICATIONS FOR CONSERVED ALLOSTERIC MECHANISMS." Journal of biological chemistry 286.8 (2011): 6201-6210.
description	12.	Vielemeyer, O. "Characterization of single chain antibody targets through yeast two hybrid." BMC biotechnology 10.1 (2010): 59-71.
description	13.	Schnitzer, J E E. "Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo." Advanced Drug Delivery Reviews 49.3 (2001): 265-80.
description	14.	Li, C. "Gold-Based Magneto/Optical Nanostructures: Challenges for In Vivo Applications in Cancer Diagnostics and Therapy." MRS bulletin 34.6 (2009): 415-421.
description	15.	Barbas, C F d. "Recent advances in phage display." Current opinion in biotechnology 4.5 (1993): 526-530.
description	16.	Liu, Z. "Polysaccharides-based nanoparticles as drug delivery systems." Advanced Drug Delivery Reviews 60.15 (2008): 1650-1662.
description	17.	Schwartz, M. "Further studies on the binding of maltose to the maltose-binding protein of Escherichia coli." European journal of biochemistry 71.1 (1977): 167-70.
description	18.	Nieba, L. "BIACORE analysis of histidine-tagged proteins using a chelating NTA sensor chip." Analytical biochemistry 252.2 (1997): 217-28.
description	19.	Griffiths, A. "Strategies for selection of antibodies by phage display." Current opinion in biotechnology 9.1 (1998): 102-108.
description	20.	Sidhu, Sachdev S S. "Phage display for engineering and analyzing protein interaction interfaces." Current opinion in structural biology 17.4 (2007): 481-487.